Trial Profile
Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- 09 Oct 2019 Status changed from active, no longer recruiting to completed.
- 05 Apr 2019 Planned number of patients changed from 30 to 20.
- 05 Apr 2019 Planned End Date changed from 10 Nov 2019 to 1 Nov 2019.